Oramed Pharmaceuticals stock (US68403P1003): Shares surged 7.98% to $2.30

Oramed Pharmaceuticals stock jumped 7.98% on July 23, 2025, closing at $2.30 from $2.13 amid positive technical signals on Nasdaq.

Oramed Pharmaceuticals stock rose 7.98% on Wednesday, July 23, 2025, climbing from $2.13 to $2.30 during trading on Nasdaq. The shares fluctuated 7.98% that day, reaching a high of $2.30 and a low of $2.13, according to StockInvest.us as of July 2025. This move followed a buy signal from a pivot bottom on July 8, 2025, with shares up 10.05% since then.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Oramed Pharmaceuticals Inc.
• Sector/industry: Biotechnology
• Headquarters/country: Israel
• Core markets: Oral drug delivery, diabetes treatments
• Home exchange/listing venue: Nasdaq (ORMP)
• Trading currency: USD

Oramed Pharmaceuticals: core business model

Oramed Pharmaceuticals develops oral delivery systems for proteins and peptides, focusing on needle-free alternatives to injectable therapies. The company's lead candidate ORMD-0801 targets type 1 diabetes via oral insulin. Listed on Nasdaq under ORMP, Oramed operates from Israel with a pipeline addressing metabolic diseases relevant to US investors through biotech innovation.

Oramed's technology uses proprietary absorption enhancers to enable oral administration, potentially improving patient compliance in the large US diabetes market. The firm has advanced several candidates through clinical stages, with partnerships enhancing its US exposure.

Main revenue and product drivers for Oramed Pharmaceuticals

Pipeline progress drives investor interest, particularly oral insulin ORMD-0801, which completed Phase 3 trials. Revenue stems from licensing deals and milestones, with no commercial products yet generating sales as of recent updates. The July 23, 2025, price surge reflects technical momentum amid biotech sector volatility on Nasdaq.

Key drivers include regulatory milestones and trial data readouts, positioning Oramed in the growing US oral biologics space valued at billions annually.

Conclusion

Oramed Pharmaceuticals stock showed strength with a 7.98% gain to $2.30 on July 23, 2025, supported by technical buy signals. The biotech focuses on oral delivery innovations with US market relevance via Nasdaq listing. Investors track pipeline updates amid volatile biotech trading, balancing potential against clinical risks.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.